Preliminary data from a study conducted at the University of Oxford indicates that the Covid-19 vaccine developed by AstraZeneca is effective against the Brazilian variant P1, a source with knowledge of the study told Reuters on March 5.
Eli Lilly’s Phase III SURPASS-2 clinical trial shows that treatment with tirzepatide, a once-weekly dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist, is associated with superior reductions in body weight and blood sugar compared with injectable semaglutide in adults with type 2 diabetes.
Shares of Ovid Therapeutics soared in trading after the company announced pharma giant Takeda signed a licensing agreement valued at $856 million to secure global rights to the investigational medicine soticlestat for the treatment of two forms of rare epilepsy.
Oyster Point’s New Drug Application (NDA) for the dry eye disease therapy OC-01 was accepted for FDA regulatory review on the back of positive Phase III data.
Novavax Chief Executive Officer Stanley Erck believes the U.S. Food and Drug Administration could grant Emergency Use Authorization (EUA) for the company’s Covid-19 vaccine by May.
Merck will have to wait to see if a Covid-19 therapeutic gained in November through the $425 million acquisition of OncoImmune can receive Emergency Use Authorization (EUA) after the U.S. Food and Drug Administration requested additional data beyond the Phase III study announced during 2020
Roivant Sciences, the umbrella company for Vivek Ramaswamy’s series of ‘vant companies, acquired Silicon Therapeutics for $450 million in Roivant equity.
The first big real-world study of the Pfizer/BioNTech vaccine to be independently reviewed shows the shot is highly effective at preventing Covid-19, in a potentially landmark moment for countries desperate to end lockdowns and reopen economies.
The COVID-19 pandemic has redefined what it means and what it takes to be a healthcare provider in a time of crisis. In a new study from McCann Health, the data from the original 2016 Truth About Doctors study was re-examined and updated, highlighting the need to focus on prioritizing the health and wellbeing of physicians to ultimately help foster a healthier public.
Many health experts believe that the Covid-19 vaccine candidate NVX-CoV237 from Novavax offers potential advantages over competitors including Pfizer-BioNTech, Moderna, Johnson & Johnson, and AstraZeneca-Oxford.